Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00371020
Other study ID # 8373
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received August 31, 2006
Last updated July 11, 2007
Start date February 2005
Est. completion date July 2007

Study information

Verified date July 2007
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

To evaluate the effect of combined 5-FU and low molecular weight heparin in infusion on the rate of retinal redetachment after silicone oil removal in cases of proliferative vitreoretinopathy (PVR).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date July 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Cases with history of vitrectomy and silicone oil injection for management of PVR who undergo silicone oil removal

Exclusion Criteria:

- any sign of retinal redetachment before silicone oil removal

- any sign of diabetic retinopathy

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
low molecular weight heparin, 5-FU


Locations

Country Name City State
Iran, Islamic Republic of Hamid Ahmadieh, MD Tehran

Sponsors (1)

Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retinal redetachment rate
Secondary visual acuity
Secondary intraocular pressure
Secondary reoperation
Secondary relative afferent pupillary defect
See also
  Status Clinical Trial Phase
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT01445028 - Isotretinoin for Proliferative Vitreoretinopathy Phase 4
Recruiting NCT00370760 - Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Phase 3
Completed NCT00000140 - The Silicone Study Phase 3
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Recruiting NCT04580147 - Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair Phase 2
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Completed NCT04136366 - The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Phase 3
Recruiting NCT06289205 - "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" Phase 1/Phase 2
Completed NCT00373282 - Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Phase 3
Completed NCT01995045 - Postoperative Pain Control Following Vitreoretinal Surgery Phase 4
Completed NCT04490876 - Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Completed NCT02192970 - Bevacizumab Against Recurrent Retinal Detachment Phase 2
Not yet recruiting NCT04682054 - Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics N/A
Recruiting NCT05660447 - A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Phase 2/Phase 3
Not yet recruiting NCT06033703 - Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment Phase 1/Phase 2
Completed NCT03727776 - Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) Early Phase 1